Northwest Biotherapeutics (NWBO): A -13% Drop in 30 Days Amid Biotech Headwinds
Key Takeaways
- NWBO stock declined -13% over the last 30 days amid low trading volume and no major catalysts, trading in a volatile range around $0.20-$0.24.
- Over the past quarter, shares fell approximately -20%, reflecting persistent operational losses and biotech sector pressures.
- Recent SEC filings highlighted substantial net losses, tight cash positions, and going concern doubts, eroding investor confidence.
- Lack of earnings releases, regulatory updates, or partnerships contributed to range-bound, downward-biased price movement.
- Broader macroeconomic factors, including high interest rates limiting biotech funding, amplified the decline.
Understanding Northwest Biotherapeutics (NWBO) and Its Place in the Market
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
From what I see in the fundamentals, the company faces ongoing challenges: minimal revenue (under $1 million TTM), high R&D burn, and negative equity from debt conversions and dilutions. This exposure to clinical risks and funding needs explains its vulnerability to sentiment shifts, as investors weigh regulatory progress against liquidity strains.
NWBO Stock Performance: Breaking Down the Last 30 Days and Quarter
Over the last 30 days, NWBO stock dropped -13%, from approximately $0.230 around early March to $0.200 currently. The movement was volatile and range-bound, with intraday swings between $0.195 and $0.240 but no sustained uptrend, on average daily volume around 2-3 million shares.
For the past quarter, shares declined -20%, from near $0.250 in early January to $0.200. The trajectory was gradual downward, punctuated by brief spikes (e.g., early January high near $0.320), amid thinning liquidity and sector headwinds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry, and the patterns align with broader biotech weakness.
Key Drivers Behind NWBO's -13% Decline in the Last 30 Days
The -13% decline stemmed from absence of fresh catalysts, leaving shares susceptible to biotech volatility. No earnings, product announcements, or partnerships emerged, with trading dominated by low volume and profit-taking near $0.24 resistance.
Recent SEC 10-Q filings underscored Q3 2025 net loss of $26.8 million on $200,000 revenue, cash at $4.56 million post-$30 million YTD burn, and "substantial doubt" on going concern status. High debt ($125.9 million liabilities) and share issuances for financing fueled dilution concerns, pressuring sentiment.
Sector influences included elevated interest rates curbing small-cap biotech funding, while no analyst upgrades countered the negativity. This fostered repeated tests of $0.200 support. One thing that stands out is how these filings continue to weigh on confidence without offsetting news.
What Shaped NWBO's -20% Quarterly Performance
The broader -20% quarterly drop reflected sustained operational headwinds and industry dynamics. Cumulative SEC disclosures painted a picture of escalating losses ($61.6 million YTD through Q3 2025), negative equity (-$108.6 million), and reliance on dilutive equity/debt conversions (e.g., 107 million shares issued).
Macro conditions, such as persistent high rates squeezing biotech valuations and fundraising, hit micro-caps like NWBO hardest. Institutional behavior showed thinning interest, with volume declining amid lack of regulatory milestones on DCVax. Competitive pressures in immunotherapy, without positive trial or partnership news, amplified the drift lower, outweighing minor spikes from speculation.
Discovering Trending AI Robots for Volatile Markets Like Biotech
In my own research and trading, I often turn to Tickeron’s Trending AI Robots page, which showcases the platform's top-performing AI-driven trading bots from hundreds available. These bots scan thousands of tickers across strategies like trend-following, mean reversion, and momentum plays, providing real-time performance metrics such as win rates, average returns, drawdowns, and timeframes from intraday to long-term. Filtered for relevance and consistency, they help me identify tools that match my risk tolerance, especially in volatile sectors like biotech. I find it valuable to explore this page to deploy or backtest bots tailored for stocks like NWBO, as it adds a layer of data-driven insight to my analysis.
NWBO Outlook: Critical Factors I'm Watching Moving Forward
Key monitors include upcoming earnings for Q4 2025 and full-year 2025, detailing cash burn and debt status. Progress on DCVax regulatory submissions (e.g., MHRA review) or manufacturing scale-up at Sawston facility could sway sentiment. Industry trends in immunotherapy approvals and partnerships remain critical. Macro shifts like interest rate cuts may ease funding pressures. Risks encompass further dilution, trial delays, or liquidity crunches; catalysts like deals or positive data could spark rebounds. I'm watching this closely for any signs of momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
NWBO sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NWBO moved below the 200-day moving average on March 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NWBO as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NWBO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NWBO entered a downward trend on April 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NWBO's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NWBO just turned positive on March 31, 2026. Looking at past instances where NWBO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NWBO advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
NWBO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (26.200). P/E Ratio (0.000) is within average values for comparable stocks, (45.671). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.767). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (303.030) is also within normal values, averaging (318.057).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NWBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NWBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of immunotherapy products
Industry Biotechnology
Advertisement